
    
      CV181-369; A 24 Week International, Open-Label Trial With a 28 Week Extension to Evaluate the
      Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in
      Subjects With Type 2 Diabetes on Metformin With or Without Sulfonylurea Therapy
    
  